• GeneDx Holdings Corp WGS.OQ reported quarterly adjusted earnings of 62 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -69 cents. The mean expectation of six analysts for the quarter was for earnings of 16 cents per share. Wall Street expected results to range from 3 cents to 34 cents per share.

• Revenue rose 66.6% to $95.64 million from a year ago; analysts expected $82.23 million.

• GeneDx Holdings Corp's reported EPS for the quarter was 23 cents​.

• The company reported quarterly net income of $5.44 million.

• GeneDx Holdings Corp shares had fallen by 0.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 51.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for GeneDx Holdings Corp is $85.00

This summary was machine generated from LSEG data February 18 at 02:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)